

Amendments to the Specification

Please replace the last paragraph on page 27 with the following, amended paragraph:

The present invention provides a compound, identified or identifiable using a method of the invention, capable of deactivating, i.e. switching off a small GTPase. Preferably the compound is a CAPRI activating peptide, capable of switching off Ras activity, most preferably consisting of or comprising a peptide selected from CVEAWD (SEQ ID NO: 1) or RVELWD (SEQ ID NO: 7) or a functional analogue, derivative or fragment thereof.

Please replace the first paragraph on page 28 with the following, amended paragraph:

The present invention provides a compound, identified or identifiable using a method of the invention, capable of promoting the activity of a small GTPase. Preferably the compound is a CAPRI inhibiting peptide capable of promoting Ras activity, i.e. activating Ras or maintaining Ras in the active (GTP-bound) state, most preferably consisting of or comprising a peptide selected from SCYPRWNET (SEQ ID NO: 5) and KDRNGTSDPFVRV (SEQ ID NO: 3), TRFPHWDEV (SEQ ID NO: 9), RDISGTSDPFARV (SEQ ID NO: 11) or a functional analogue, fragment or derivative thereof.

Please replace the third full paragraph on page 36 with the following, amended paragraph:

Figure 2. Alignment of β 1-6 of the PKC β C2B domain (SEQ ID NO: 13) with CAPRI (SEQ ID NO: 14) and GAP1^m (SEQ ID NO: 15) (PKC is type I topology). Boxed regions indicate highly conserved RACK binding sequences identified in PKC β .

Please replace the last paragraph on page 39 with the following, amended paragraph:

The peptides chosen for investigation included the CAPRI activating peptide CVEAWD (pseudo-RACK1) (SEQ ID NO:1) and CAPRI inhibitory peptides KDRNGTSDPFVRV (C2-2) (SEQ ID NO: 3) and SCYPRWNET (C2-4) ~~SEQ ID NO: 4~~ (SEQ ID NO: 5).